About
Gileade specializes in high-stakes gene-editing therapeutics, delivering CRISPR-derived cures for planetary plagues and enhancing human biology for deep-space colonization. Their proprietary 'Salind' reasoning AI now compresses a decade-long drug discovery cycle into months, focusing on protein engineering that allows humans to survive in vacuum or toxic atmospheres.
How it started
Disillusioned by the slow pace of interstellar biotech, Dr. Arin Voss merged a down-on-its-luck biotech firm with a rival German successor during the 2326 activist takeover wave. Originating in the humid rot of Xyloph's underside, they successfully mass-produced a lung-regeneration sequence that allowed miners to survive the acidic mist, turning a desperate survival ploy into a galactic monopoly.
People at Gileade
Bubblum Sweatstorm
Radical Transparency Auditor @ Gileade | Optimizing the Survival Margin | Let's Audit the Patentable Sequence
Squelxa Kellis
Optimizing Biological Decay @ Gileade | CRISPR Gene Editing | Tissue Bioprinting
Fungora Thrums
Pioneering Genomic Transformation @ Gileade | Scalable Metabolic Optimization | Let's Win! 🧬
Daniyel O'Dax
CEO of Gileade | Driving Portfolio Innovation and High-Impact Therapeutic Delivery Across the Galaxy 🧬
